Search Results

Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company”, a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, announced that its Board of Directors has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-4.

Neurogene Inc. (NASDAQ: NGNE) (“Neurogene”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the closing of its merger with Neoleukin Therapeutics, Inc. (“Neoleukin”).

Neoleukin Therapeutics, Inc., today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-5.

Neurogene Inc. and Neoleukin Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Neoleukin Therapeutics, Inc., today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value.

Neoleukin Therapeutics, Inc., “Neoleukin”, announced an oral presentation at the upcoming American Society of Hematology Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana.

Neoleukin Therapeutics, Inc. announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de novo IL-2/IL-15 agonist, and focus on advancing next-generation de novo protein therapeutics based on Neoleukin’s expertise in designing and testing novel cytokine mimetics and experience with advanced machine learning.

Neoleukin Therapeutics plans to slash its workforce by about 40% and drop NL-201, a de novo IL-2/IL-15 agonist currently in Phase I, according to its third-quarter report.

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced financial results for the second quarter ended June 30, 2022 and a midyear corporate update.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets.